Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | USP5 | P45974 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683687 | 1.00 | CTSG (0.37) | CTSGCMA1GLAGBA1ALDH1A1 | |
| SCHEMBL5278230 | 1.00 | CTSG (0.37) | CTSGCMA1GLAGBA1ALDH1A1 | |
| SCHEMBL5349386 | 0.88 | MEN1 (0.36) | GLAGBA1ALDH1A1MEN1KMT2A | |
| SCHEMBL2684907 | 0.86 | GLA (0.40) | CTSGCMA1GLAGBA1ALDH1A1 | |
| SCHEMBL5399837 | 0.86 | GLA (0.41) | GLAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2682454 | 0.86 | GLA (0.41) | GLAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2683681 | 0.81 | GLA (0.43) | CTSGCMA1GLAALDH1A1MEN1 | |
| SCHEMBL2682607 | 0.81 | GLA (0.41) | CTSGCMA1GLAALDH1A1MEN1 | |
| SCHEMBL5361146 | 0.81 | GLA (0.41) | CTSGCMA1GLAALDH1A1MEN1 | |
| SCHEMBL3903708 | 0.73 | GAA (0.35) | GLAALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | HEROLD PETER (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | CTSG 16/4885CMA1 144/4885GLA 333/4885 |
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | CTSG 438/4885CMA1 75/4885GLA 2105/4885 |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGTR1, AGTR2 | CTSG 426/4885CMA1 70/4885GLA 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.